Wedbush analyst David Nierengarten lowered the price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Mersana (MRSN) PT Lowered to $7 at H.C. WainwrightMarch 11, 2019 8:05 AM JPMorgan Downgrades Mersana (MRSN) to UnderweightMarch 11, 2019 5:04 AM Form S-8 Mersana Therapeutics, March 8, 2019 4:25 PM Form 10-K Mersana Therapeutics, For: Dec 31March 8, 2019 4:12 PM Mersana (MRSN) PT Lowered to $12 at BairdMarch 8, 2019 12:27 PM Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues MissMarch 8, 2019 6:08 AM